HIV Clinical Studies Beth Israel Listing St. Luke's-Roosevelt Listing Beth Israel For complete information about Beth Israel's AIDS Clinical Trials Unit, click here or call (800) 483-7339. Anti-HIV Therapy Experienced and Virologically Suppressed ACTG A5197; A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Antiretroviral Effect of Immunization with the MRK Ad5 HIV-1 gag Vaccine in HIV-1 Infected Individuals who Interrupt Antiretroviral Drug Therapy INCB 8721 RVT-203; A Placebo-Controlled, Double-Blind, Parallel Dose Group Study Exploring the Safety, Tolerability, and Virological Effect of 50, 100, and 200 mg Reversettm (RVT, an NRTI) in HIV-Infected Antiretroviral Therapy-Experienced Subjects when used in Combination with Other Antiretroviral Agents Wyeth Protocol 6112K2-100-US; Evaluating an HIV CTL Multi-Epitope Peptide (MEP) Vaccine Formulated with RC529-SE and GM-CSF Given to HIV Positive Adults Receiving Stable HAART   Studies for Women Anti-HIV Therapy Experienced and Virologically Failing ACTG A5211; A Phase II, Randomized, Double-Blind Study of the Safety and Efficacy of SCH 417690 (an oral HIV entry inhibitor) in HIV-Infected, Treatment-Experienced Subjects ACTG A5216; A Randomized Phase II Study of the Safety, Immunologic and Virologic Effects of Cyclosporine A in Conjunction with Trizivir and Kaletra versus Trizivir and Kaletra Alone during Primary HIV-1 Infection ACTG A5146: Evaluating the Impact of Therapeutic Drug Monitoring (TDM) on Virologic Response to a Salvage Regimen. ACTG A5165; A Randomized, Double-Blind, Placebo-Controlled Pilot Study of DAPD (amdoxavir, an NRTI)) versus DAPD plus Mycophenolate Mofetil (MMF) in Treatment-Experienced Subjects Progenics Protocol TT2001: A Phase II Pharmacokenetic Study of PRO 542 (A Fusion Protein) Complications of HIV Treatment Studies ACTG A5157; Using the Amino Acid Acetyl-L-Carnitine for the Treatment of Dideoxynucleoside (d-drug) Associated Peripheral Neuropathy ACTG A5178; Suppressive Long-Term Antiviral Management of Hepatitis C Virus (HCV) and HIV-1 Co-Infected Subjects (SLAM-C) ACTG A5186; A Phase II Trial of the Effect of Combination Therapy with Fish Oil Supplement and Fenofibrate on Triglyceride (TG) Levels in Subjects on Highly Active Antiretroviral Therapy (HAART) who are not Responding to Either Fish Oil or Fenofibrate Alone Pharmacokinetic Studies Progenics Protocol TT2001: A Phase II Pharmacokenetic Study of PRO 542 (A Fusion Protein) ACTG A5177; An Observational Study of the Pharmacokinetics (PK) of Efavirenz, Nevirapine, and Lopinavir/Ritonavir in HIV-lnfected Subjects; Requiring Hemodialysis For more information on the above studies, please email us at sbarnett@chpnet.org or call (212) 420-4519. St. Luke's-Roosevelt HIV Obesity Treatment Study HIV Clinical Trials (3) Antivirals for HIV Infection AIDS Management Trial Anemia Study Mouthrinse Trial Combination of Antivirals Trial Weight Loss & Antivirals HIV Brain Bank For more information on these studies, send inquiries to: info@WeHealNewYork.org